Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer.
Saved in:
| Title: | Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer. |
|---|---|
| Authors: | Sachdeva M; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Hospital, Singapore, Singapore., Tan DSP; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Hospital, Singapore, Singapore.; Cancer Science Institute (CSI), National University of Singapore (NUS), Singapore, Singapore. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jul 01; Vol. 32 (13), pp. 2525-2526. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-26-0534 |
